China's Gliclazide Market 2018-2022: Sales Value of Gliclazide Kept Rising After the Drug Entered China, and Exceeded CNY 200 Million in 2017
DUBLIN, Sept. 26, 2018 /PRNewswire/ --
The "Investigation Report on China's Gliclazide Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The overweight population and the incidence of type 2 diabetes are growing in China as the economy develops, the population ages, and the lifestyle changes. The number of people with type 2 diabetes exceeded 110 million at the end of 2017, and is still rising.
Taken by mouth, Gliclazide is a second-generation sulfonylurea to treat diabetes by stimulating insulin secretion from pancreatic -cells. It can protect pancreatic -cells from the apoptosis caused by hyperglycemia, and prevent atherosclerosis (build-up of fatty deposits in the arteries) caused by type 2 diabetes.
Developed by French company Servier, Gliclazide (trade name: Diamicron) was first launched in France in 1972, and entered China in the 1980s. In China, at least 200,000 people with type 2 diabetes are taking Gliclazide every year. In 1987, Tianjin Huajin Pharmaceutical Factory (now known as Tianjin Huajin Pharmaceutical Co., Ltd.) started cooperating with Servier and Tianjin Pharmaceutical Station to produce Gliclazide (Diamicron), a new drug to treat type 2 diabetes.
With the support of Servier, the company has been taking the leading position on China's Gliclazide market. Also dominating the market are Servier and Servier (Tianjin) Pharmaceutical Co., Ltd., the joint venture of Servier and Tianjin Huajin Pharmaceutical Co., Ltd.
According to the researcher, the sales value of Gliclazide kept rising after the drug entered China, and exceeded CNY 200 million in 2017. It is expected that China's Gliclazide market will continue to grow as the incidence of type 2 diabetes rises.
Key Topics Covered:
1 Relevant Concepts of Gliclazide
1.1 Indications for Gliclazide
1.2 Development History of Gliclazide in China
1.3 Governmental Approval of Gliclazide in China
2 Sales of Gliclazide in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Gliclazide by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
3 Analysis on Major Gliclazide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Gliclazide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Servier
3.2.1 Enterprise Profile
3.2.2 Sales of Servier's Gliclazide in China
3.3 Servier (Tianjin) Pharmaceutical Co., Ltd.
3.4 Tianjin Huajin Pharmaceutical Co. Ltd.
3.5 Nanchang Helioeast Pharmaceutical Co., Ltd.
3.6 Guilin Hwasun Pharmaceutical Co., Ltd.
4 Prices of Gliclazide in China, 2017-2018
4.1 Servier (Diamicron)
4.2 Servier (Tianjin) Pharmaceutical Co., Ltd. (Diamicron)
4.3 Tianjin Huajin Pharmaceutical Co. Ltd. (Diamicron)
4.4 Nanchang Helioeast Pharmaceutical Co., Ltd. (Hongxuyang)
4.5 Guilin Hwasun Pharmaceutical Co., Ltd. (Xieerping)
5 Prospect of China's Gliclazide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/research/n23q72/chinas?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article